New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
04:55 EDTLIFE, LIFE, LIFE, CYCC, CYCC, CYCC, BLUE, BLUE, BLUE, PJC, PJC, PJC, STEM, STEM, STEM, ATHX, ATHX, ATHX, NBS, NBS, NBS, ONVO, ONVO, ONVO, CYTX, CYTX, CYTX, ISCO, ISCO, ISCOEBD Group to hold a conference
Biotech Showcase 2014 is being held in San Francisco on January 13-15.
News For LIFE;CYTX;ONVO;NBS;ATHX;STEM;PJC;BLUE;CYCC;ISCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
07:07 EDTONVOMecklerMedia to hold a conference
Inside 3D Printing Conference is being held in Santa Clara, California on October 21-23.
07:06 EDTBLUEFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 15, 2014
14:47 EDTCYTXSabby reports 9.99% passive stake in Cytori Therapeutics
Subscribe for More Information
October 14, 2014
07:04 EDTBLUEbluebird bio says first patient with sicle cell disease undergoes infusion
Subscribe for More Information
06:05 EDTNBSBioLife Solutions biopreservation products used at Progenitor Cell Therapy
BioLife Solutions (BLFS) provided an update on use of the company's HypoThermosol storage/shipping media and CryoStor cryopreservation freeze media by Progenitor Cell Therapy, or PCT, a wholly owned subsidiary of NeoStem (NBS) a leader in the emerging cellular therapy field.
October 13, 2014
15:24 EDTPJCNotable companies reporting before tomorrow's open
Subscribe for More Information
October 9, 2014
07:10 EDTCYCCCyclacel announces DSMB recommendation to continue Sapacitabine Phase 3 trial
Cyclacel Pharmaceuticals announced that the independent Data and Safety Monitoring Board, or DSMB, for the company's Phase 3 SEAMLESS study in acute myeloid leukemia, or AML, has completed its fourth planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 317 randomized patients with at least 60 days of follow-up and noted that no safety or efficacy concerns were identified.
October 8, 2014
08:04 EDTCYTXCytori Therapeutics raises $13.5M in a registered direct offering
Subscribe for More Information
October 7, 2014
08:14 EDTSTEMStemCells initiates Phase II clinical trial using HuCNS-SC
Subscribe for More Information
07:24 EDTNBS, ONVO, BLUE, STEM, ATHXAlliance for Regenerative Medicine
Subscribe for More Information
07:16 EDTNBS, BLUEBiotech Industry Organization to hold a forum
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use